Close Menu

NEW YORK – Aspira Women's Health reported after the close of the market on Thursday that its fourth quarter revenues were up 11 percent year over year.

Separately, the Austin, Texas-based company said it has signed an agreement with the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate their microRNA technology combined with Aspira's current technologies in order to develop a highly sensitive and specific high-risk, early detection test for ovarian cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

Apr
20
Sponsored by
Olink

This webinar will discuss a study that sought to identify early biomarkers for cancer by analyzing pre-diagnosis samples from seemingly healthy individuals who were later diagnosed with cancer.

Apr
23
Sponsored by
Isoplexis

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

May
10
Sponsored by
MeMed

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

May
20
Sponsored by
ACD

This webinar will present a research project that is using spatial transcriptomics to discern the molecular mechanisms underlying fear memory.